doi: 10.1073/pnas.85.18.6612.
Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A
Affiliations
- PMID: 3045820
- PMCID: PMC282027
- DOI: 10.1073/pnas.85.18.6612
Item in Clipboard
Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A
Proc Natl Acad Sci U S A.
1988 Sep.
Abstract
The protease encoded by the human immunodeficiency virus (HIV) processes the viral gag and gag-pol protein precursor by posttranslational cleavage. In this study we have demonstrated by site-specific mutagenesis (Asp----Thr) and by pepstatin A inhibition that the recombinant HIV protease is an aspartic-type protease. Furthermore, incubation of HIV-infected H9 cells with pepstatin A inhibited part of the intracellular processing of the HIV gag protein yet had no apparent toxicity on HIV-infected cells during 48 hr of incubation.
Similar articles
-
Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A.FEBS Lett. 1989 Apr 24;247(2):349-52. doi: 10.1016/0014-5793(89)81368-7. FEBS Lett. 1989. PMID: 2469601
-
Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.Antimicrob Agents Chemother. 2006 Jun;50(6):2207-9. doi: 10.1128/AAC.00022-06. Antimicrob Agents Chemother. 2006. PMID: 16723585 Free PMC article.
-
Biological activity of aspartic proteinase inhibitors related to pepstatin.Acta Biol Med Ger. 1981;40(10-11):1547-53. Acta Biol Med Ger. 1981. PMID: 6805191
-
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.J Med Chem. 1985 Mar;28(3):263-73. doi: 10.1021/jm00381a001. J Med Chem. 1985. PMID: 3882966 No abstract available.
-
Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases.FEBS Lett. 1989 Apr 10;247(1):113-7. doi: 10.1016/0014-5793(89)81251-7. FEBS Lett. 1989. PMID: 2651157
Cited by
-
beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease.Proc Natl Acad Sci U S A. 1990 Dec;87(24):10023-7. doi: 10.1073/pnas.87.24.10023. Proc Natl Acad Sci U S A. 1990. PMID: 2124694 Free PMC article.
-
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.Proc Natl Acad Sci U S A. 1989 Dec;86(24):9752-6. doi: 10.1073/pnas.86.24.9752. Proc Natl Acad Sci U S A. 1989. PMID: 2690072 Free PMC article.
-
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.Antimicrob Agents Chemother. 1993 Jan;37(1):71-7. doi: 10.1128/AAC.37.1.71. Antimicrob Agents Chemother. 1993. PMID: 8381640 Free PMC article.
-
Tandem ketone reduction in pepstatin biosynthesis reveals an F420H2-dependent statine pathway.Nat Commun. 2025 May 15;16(1):4531. doi: 10.1038/s41467-025-59785-0. Nat Commun. 2025. PMID: 40374670 Free PMC article.
-
Proteaselike sequence in hepatitis B virus core antigen is not required for e antigen generation and may not be part of an aspartic acid-type protease.J Virol. 1989 Jun;63(6):2598-604. doi: 10.1128/JVI.63.6.2598-2604.1989. J Virol. 1989. PMID: 2657101 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
